The current record supports company, publicly released project and assurance facts. It does not establish deployment, adoption, clinical validation or public benefit.
Only source-linked project information already in the public domain appears here. It is not presented as proof of customer adoption, clinical effect or wider public impact.
NEUVIOR has been selected for non-dilutive support for defined R&D project work. This site links only project-level information already in the public domain. Maximum award value, eligible project cost, company contribution and cash received are different facts; Award ceilings and eligible project costs are not cash received, revenue, customer adoption or outcomes.
Innovate UK project; the public project record is closed.
Innovate UK project; the public project record is closed.
NEUVIOR’s 2025–26 NHS DSP Toolkit submission; not an NHS endorsement.
The PHARMORIS and VIONIX ZERO public UKRI project records are closed. This page does not derive or publish company-wide funding totals.
Maximum award value, eligible project cost, company contribution and cash received are different facts; Award ceilings and eligible project costs are not cash received, revenue, customer adoption or outcomes.
The distinction below is deliberate: a public input can be verified without proving that a product or programme has created impact.
PHARMORIS is under controlled, non-production development. No customer, live deployment or production readiness is claimed.
The DSP Toolkit publication is an assurance record, not NHS endorsement, clinical validation or evidence of product deployment.
The public record relates to completed feasibility work. It is not presented as an active manufacturing or trials programme.
Absence of an outcome claim is a status boundary, not a prediction about future results.
This is a direction for work, not evidence that the intended effect has already been achieved.
The agenda is to help medicines teams connect identifiable evidence, authorised decisions and visible follow-through. Software may organise evidence and options; accountable people retain judgement and approval.
Future programmes advance only when evidence earns the next gate. That protects public value by keeping focus, responsibility and uncertainty visible.
A claim should survive a sceptical reader, a source check and the passage of time.
Software may organise evidence and options; accountable people retain judgement and approval.
NEUVIOR and VARUNÉ Bio are the two company priorities. Each programme advances when its evidence and resources justify the next step.
Uncertainty is not a branding flaw. Making it visible protects decisions, partners and reputation.
Impact should only enter the public record when the evidence is proportionate to the claim. These are the principal gaps still to close.
Verifiable deployment evidence, with an accountable organisation and a clear description of what is actually in use.
Evidence of real workflow use and authorised adoption, separated from a founder statement, demo or development milestone.
A stated baseline, measurement method, observation period and source before any benefit or system effect is reported.
Independent, clinical, regulatory or assurance evidence proportionate to the specific public claim being made.
This is an evidence agenda. It does not confirm that any of these gates has been met.